Fig. 2

Expression of lnc-GNAT1-1 in CRC patients’ plasma, as well as its expression in CRC cell lines and its subcellular location. a Expression of lnc-GNAT1-1 was decreased in plasma of CRC patients than the normal controls (relative expression levels, 0.33 vs 0.72, P < 0.001). b Plasma lnc-GNAT1-1 levels were decreased with the TNM stages advanced. Its relative expression levels in stage I+ II, stage III and stage IV patients were 0.56, 0.25, 0.10, respectively. c ROC curve analysis of lnc-GNAT1-1 for discriminative ability between CRC cases and normal controls, with an AUC of 0.702. d Relative expression of lnc-GNAT1-1 in 6 CRC cell lines, with the highest in SW480, and the lowest in RKO cells. e Subcellular fractionation for lnc-GNAT1-1 in SW480 and LoVo cells, U6 and GAPDH were set as controls. Lnc-GNAT1-1 has a predominate localization in the nucleus. *P < 0.05, ***P < 0.001